GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
The company possesses a wide moat derived from its deep-rooted brand equity in legacy products like Augmentin and Calpol, combined with a dominant regulatory and scale advantage in the private vaccine market. This is corroborated by exceptionally high and stable average ROCE of 41.7% and persistent double-digit net margins, indicating significant barriers to entry for competitors.
Management prioritizes high-dividend payouts, as evidenced by a final dividend of 57 INR per share, while maintaining a debt-free balance sheet. Reinvestment is focused on high-margin specialty areas like oncology and adult vaccines rather than capital-intensive manufacturing expansion.
The investment collapsed as the Indian government expanded the National List of Essential Medicines (NLEM) to cover nearly the entire legacy portfolio, stripping away pricing power and crushing margins. Simultaneously, the high-margin specialty and vaccine segments failed to offset these losses as competitors successfully bypassed the brand moat with cheaper, bio-equivalent alternatives. The company's refusal to reinvest in manufacturing, opting instead for high dividends, left it with a brittle supply chain that couldn't survive a series of third-party disruptions, leading to permanent market share loss in key categories like Augmentin.
RichFakir rates Glaxosmithkline Pharmaceuticals Ltd's business quality as wonderful — 74/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as wide.
On our model, Glaxosmithkline Pharmaceuticals Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Glaxosmithkline Pharmaceuticals Ltd is: Watch — wait for price. A wonderful business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Glaxosmithkline Pharmaceuticals Ltd's fair value is about ₹857 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →